Abstract
After the 1918 Spanish Flu pandemic caused by the H1N1 virus, the recent coronavirus disease 2019 (COVID-19) brought us to the time of serious global health catastrophe. Although no proven therapies are identified yet which can offer a definitive treatment of the COVID-19, a series of antiviral, antibacterial, antiparasitic, immunosuppressant drugs have shown clinical benefits based on repurposing theory. However, these studies are made on small number of patients, and, in majority of the cases, have been carried out as nonrandomized trials. As society is running against the time to combat the COVID-19, we present here a comprehensive review dealing with up-to-date information of therapeutics or drug regimens being utilized by physicians to treat COVID-19 patients along with in-depth discussion of mechanism of action of these drugs and their targets. Ongoing vaccine trials, monoclonal antibodies therapy and convalescent plasma treatment are also discussed. Keeping in mind that computational approaches can offer a significant insight to repurposing based drug discovery, an exhaustive discussion of computational modeling studies is performed which can assist target-specific drug discovery.
Graphic abstract
Similar content being viewed by others
Introduction
A form of pulmonary disease was first reported in China from a city called Wuhan in the Hubei Province on December 31, 2019 [1]. The deadly disease was later termed as COVID-19 by the World Health Organization (WHO) on February 11, 2020. The identified causative novel coronavirus (2019-nCoV) is termed as severe acute respiratory syndrome-related coronavirus SARS-CoV-2 as it shares around 79.6% of genome similarity with SARS-CoV which also previously emerged in China during 2002–2003 [2]. With the announcement of COVID-19 as ‘Global Pandemic’ by WHO on March 11, 2020, SARS-CoV-2 has eventually affected 212 countries and territories around the world and 2 international conveyances. As of August 13, 2020, 20,881,635 cases have been confirmed with 748,503 deaths and 13,771,549 recovery cases, while among the active cases, 6,297,028 cases are in mild condition and 64,555 cases in a serious or critical condition [3] (Fig. 1a).
The literature reported seven coronaviruses (CoVs) that are known to cause human disease where the strains 229E (α-CoV), HKU1 (β-CoV), OC43 (β-CoV) and NL63 (α-CoV) caused mild infections of the upper respiratory tract in humans [4]. On the contrary, other two strains SARS-CoV (occurring in 2002–2003) and MERS-CoV (Middle East respiratory syndrome occurring in 2012) and the newly identified SARS-CoV-2 belonging to β-CoV have caused serious health threat and fatality [5]. The present scenario and available pathophysiology specify that SARS-CoV-2 is highly transmittable and contagious than its progenitor affecting not only the respiratory system but also the gastrointestinal system, central nervous system, kidney, heart and liver leading to multiple organ failure [6]. The SARS-CoV-2 spike S glycoprotein has 72% identical sequence with human SARS with a unique furin-like cleavage site, which is absent in other SARS-like CoVs [7]. The Cryo-EM structural evidence has revealed that SARS-CoV-2 has 10–20 times higher binding affinity to the ACE2 receptor than SARS-CoV which may lead to higher transmission and contagiousness [8]. Therefore, blocking of the isolated viral S protein at its host receptor region and/or binding within the S protein-ACE2 interface are the two most important strategies to design probable drugs for COVID-19 (Fig. 1b) [9]. The SARS-CoV-2 virus replicates via multiple processes after entering into the host cell, and the proteins associated with these replication steps are the principal targets to treat the infected patients by blocking the viral replication. The replication-associated proteins are [10]:
-
a.
Translation of genomic RNA,
-
b.
Proteolysis of the translated polyprotein with viral 3C-like proteinase,
-
c.
Replication of genomic RNA with the viral replication complex which comprises 3′-to-5′ exonuclease, RNA-dependent RNA polymerase (RdRp), endoRNAse and helicase, 2′-O-ribose methyltransferase,
-
d.
Assembly of viral components.
Along with the above-mentioned targets, the most commonly employed drug targets and drug discovery strategies employed all over the world right now are illustrated in Fig. 2.
Presently, there is no specific treatment or approved drugs available to treat COVID-19. In most of the active cases, physicians are relying on symptom-based treatment for mild cases and primarily oxygen therapy (if required, with ventilator support) for critically ill patients. A set of approved marketed drugs like hydroxychloroquine (HCQ) [11, 12], chloroquine (CLQ) [12], combination of HCQ and azithromycin [13], remdesivir [14], lopinavir [15] and ritonavir [15] are being evaluated for the infection treatment; their clinical trials are also going on in different pharmaceutical industries. A series of new vaccines are also under clinical trial such as mRNA-1273 [16], Ad5-nCoV [17] and ChAdOx1 nCoV19 [18] along with existing Bacillus Calmette–Guerin (BCG) vaccine [19, 20] to check its efficiency in COVID-19. Due to severity and contagious nature of the SARS-CoV-2, researchers are exploring multiple in silico approaches and artificial intelligence [21,22,23,24,25,26] with the aim of identifying target-specific and potent therapeutic agents to speed up the discovery process. The RCSB protein data bank (PDB) (www.rcsb.org) has already deposited around 110 protein crystal structures associated with SARS-CoV-2 and COVID-19 to allow understanding important structural binding sites which can be explored in rational designing of small molecules.
The current review discusses the most updated and probable drug candidates which are being experimentally used to treat patients in different parts of the world. Also, their possible targets and pharmacological mechanisms of action which might not be clear in many cases and their pathophysiology along with the details about the status of convalescent plasma treatment and ongoing vaccine trials are discussed. We have compiled up-to-date in silico studies providing information related to computational tools, employed protein crystal structure used in the study followed by probable future drug candidates evolved from the repurposed virtual screening (VS) study employing docking, molecular dynamics (MD) and homology modeling. Therefore, the details related to SARS-CoV-2 transmission, protein structures, epidemiology, disease spectrum, diagnosis and testing are not discussed here at all as they have already been discussed in multiple literatures and separate reviews [1, 2, 4,5,6,7, 27,28,29]. The present review is significantly different from the other recently published ones on a similar topic in that it covers and gives emphasis on the in silico modeling studies in search of drugs against COVID-19. Thus, this paper provides an important source for the knowledge about possible drug candidates and vaccines along with their targets and pathophysiology information.
Investigational drugs or combination of drugs against COVID-19 up-to-date
At the time of writing this article, there are no clinically approved drugs or vaccine available for the treatment of COVID-19 [30]. However, there are many drugs under trial for the treatment of COVID-19 (chemical structures 1–19 in Figs. 3, 4, 5) including angiotensin II type I receptor (AT1R) blockers, antiviral drugs, antimalarial drugs, interferon, IL-6 inhibitors, corticosteroids, ascorbic acid, some antibacterial antibiotics, etc. An up-to-date list of drugs under trials against COVID-19 with their targets, mechanisms of action, the developer companies or institutions, uses and recent status are tabulated in Table 1. Several industries and research institute are also trying to develop miscellaneous drugs and/or therapeutics agents, followed by investigation of the effectiveness of combination of drugs listed under Box 1. Among these tabulated drugs, most effective ones are discussed here. Mechanisms of different categories of drugs used in COVID-19 patients on various stages of SARS-CoV-2 life cycle are schematically depicted in Fig. 6.
The entry of SARS-CoV-2 to the host cell can occur in two ways, i.e., either via plasma membrane fusion or via endosomes (endocytosis blockers: CLQ and HCQ) (Fig. 6). In both ways, spike proteins (S1, S2) of SARS-CoV-2 mediate attachment to the membrane of a host cell and engage angiotensin-converting enzyme 2 (ACE2) as the entry receptor. Inhibitors like convalescent plasma, monoclonal antibodies bind to the spike glycoprotein, thus preventing the viral entry. When virions are taken up into endosomes, the spike protein can be activated by the cellular serine protease TMPRSS2 in close proximity to the ACE2 receptor, which initiates fusion of the viral membrane with the plasma membrane. Camostat mesylate inhibits the TMPRSS2 receptor. The plasma membrane fusion entry is less likely to trigger host cell antiviral immunity and therefore more efficient for viral replication. After the viral RNA is released into the host cell, polyproteins are translated. The coronavirus genomic RNA encodes non-structural proteins that have a critical role in the synthesis of viral RNA and structural proteins which are important for virion assembly. First, polyproteins are translated and cleaved by some of proteases like 3CLpro, PLpro, etc. (lopinavir, ritonavir and darunavir act as inhibitors of this step) to form RNA replicase-transcriptase complex. The non-structural protein RdRp is responsible for replication of structural protein RNA. (Remdesivir, favilavir and ribavirin act as inhibitors of this enzyme). Structural proteins S1, S2, envelope and membrane are translated by ribosomes that are bound to the endoplasmic reticulum (ER) and presented on its surface as preparation of virion assembly. The nucleocapsids (N) remain in cytoplasm and are assembled from genomic RNA. They fuse with the virion precursor which is then transported from the ER through the Golgi apparatus to the cell surface via small vesicles. The mature virions are then released from the infected cell through exocytosis, and then, they search another host cell (Fig. 6).
Angiotensin II type I receptor (AT1R) blockers
SARS-CoV-2 has transmembrane spikes (S protein). The spikes attached to the lipid membrane of the coronavirus recognize a host cell to attach and infect it with its viral RNA. The attachment of the coronavirus S protein to angiotensin converting enzyme 2 (ACE2) at its cellular binding site promotes the entry into human cells. The S protein contains two subunits such as an N-terminal S1 subunit which is responsible for receptor-virus binding and a C-terminal S2 subunit which is responsible for the fusion of virus with cell membrane [31, 32]. The S1 subunit has two domains such as a receptor-binding domain (RBD) and an N-terminal domain (NTD). At the time of infection, at first coronavirus binds to the human cell through interaction between the cell ACE2 receptor and S1-RBD of coronavirus. As a result, conformational changes in the S2 subunit are triggered followed by virus-cell fusion and entry into the target cell. ACE2 is a natural protein present in the lungs and the intestine (epithelial cells), and in the heart and the kidneys (endothelial cells). ACE2 regulates the blood pressure by converting angiotensin molecules. It was found that the coronavirus which caused the SARS outbreak in 2002 also binds to the same ACE2 molecule, but in case of SARS-CoV-2, the binding affinity is 10 to 20 times more on human cells than the spike from the SARS virus of 2002, which makes it a suitable target for COVID-19. Due to the high affinity of this virus to human cells, it is spread without any difficulty from one person to another than the earlier virus [33].
The entry of SARS-CoV-2 to the host cells via binding with ACE2 enzyme leads to ACE2 down-regulation. As a result, angiotensin II is produced excessively by the correlated enzyme ACE1, while a lower amount of ACE2 is not capable of transforming it to the vasodilator heptapeptide angiotensin 1–7. Thus, expression of higher ACE2 resulting from frequently medicating COVID-19 patients with AT1R blockers may resist them against acute lung injury. This can be described by following two complementary mechanisms: (1) blocking the excessive angiotensin II-mediated AT1R activation caused by the viral infection, (2) upregulation of ACE2 decreasing angiotensin II production by ACE and enhancing the production of the vasodilator angiotensin 1–7 [34]. The role of ACE2 to enter the coronavirus into the host cell and mechanism of action of ACE2 inhibitors to control the COVID-19 are depicted in Fig. 7.
The SARS-CoV-2 uses the S protein to facilitate viral entry into the host cells. The pathogen S protein consists of two subunits S1 and S2, of which “S1” allows entry of pathogen and binding of S protein to ACE2 (cellular receptor) (Fig. 7). In addition, the entry requires S protein priming by cellular proteases, which is responsible for cleavage of S protein. After this, “S2” subunit employs fusion of viral and cellular membranes. SARS-CoV-2 engages ACE2 as the entry receptor that can be blocked by ACE2 inhibitors and Arbidol, and it employs the cellular serine protease TMPRSS2 for S protein priming which is inhibited by camostat mesylate (Fig. 7). Conclusively, SARS-CoV-2/ACE2 interface occurs in the molecular level, and the efficiency of ACE2 usage is a key determinant of SARS-CoV-2 transmissibility.
Although it is widely accepted that coronavirus enters into the host cell through the ACE2 receptor, due to limited number of studies, it is yet to establish how ACE2, AT1 and AT2 receptors exert their activities in coronavirus-induced diseases [35, 36]. Thus, ACE2 inhibitors and AT1 receptor antagonists [e.g., L-163491 as a partial antagonist of AT1 receptor and partial agonists of AT2 receptor; losartan, valsartan, irbesartan, candesartan cilexetil, telmisartan, and eprosartan (FDA-approved AT1 receptor blockers)] may be used as important drug candidates to control lung injury of COVID-19 patients [34]. The binding of viral S protein with its receptor ACE2 on host cells followed by viral endocytosis into the cells may also be a possible drug target. For example, the broad-spectrum antiviral drug Arbidol recently entered the clinical trial for the treatment of SARS-CoV-2 which may act by inhibiting virus-host cell fusion, thus preventing the viral entry into host cells against influenza virus [37,38,39].
Camostat mesylate
The serine protease TMPRSS2 produced by the host cells plays a key role for cell entry of coronaviruses by S protein priming to the receptor ACE2 binding in human cells (Fig. 7). A recent study shows that camostat mesylate, a clinically approved inhibitor of TMPRSS2 (responsible for S protein priming), has been able to block SARS-CoV-2 infection of lung cells. Thus, this drug may be a potential drug candidate for COVID-19 [40].
Remdesivir
Remdesivir, a nucleoside analog and a monophosphoramidate prodrug of remdesivir-triphosphate (RDV-TP) developed by Gilead Sciences Inc. (USA), was previously tried for the Ebola virus disease, and it showed promising effects in MERS and SARS. It acts by inhibiting RNA-dependent RNA polymerases (RdRp). Incorporation of this drug into nascent viral RNA chain causes premature termination. For incorporation of remdesivir-TP into nascent viral RNA chains, it competes with adenosine-triphosphate. After incorporation into the viral RNA at position i, remdesivir-triphosphate arrests RNA synthesis at position i + 3. Due to the incorporation of 3 additional nucleotides after RDV-TP, it does not cause instant chain termination because these three additional nucleotides may protect the inhibitor from excision by the viral 3′–5′ exo-ribonuclease activity (Fig. 6). Recent reports showed that the EC90 value of remdesivir against COVID-19 in VeroE6 cells was 1.76 µM, half-cytotoxic concentration (CC50) was greater than 100 µM, and the selective index (SI) was greater than 129.87, suggesting that its working concentrations are likely to be achieved in nonhuman primate (NHP) [14, 41]. This drug is also able to inhibit virus infection proficiently in human liver cancer Huh-7 cells sensitive to COVID-19. A recent case study revealed that treatment with remdesivir improved the clinical condition of the first patient infected by SARS-CoV-2 in the USA [42]. A recent in vitro data showed that remdesivir and chloroquine (CQ) phosphate are capable of inhibiting SARS-CoV-2 infection [14]. Remdesivir is currently being studied in Phase-III clinical trials against SARS-CoV-2 in Wuhan, China, as on February 4, 2020, and in the USA.
Chloroquine/hydroxychloroquine
Chloroquine (CLQ) and hydroxychloroquine (HCQ) have received deep attention because of positive results from some small studies. An antimalarial drug, CLQ, has recently been reported to have potential in vitro activity against SARS-CoV-2. CLQ protects from viral infection by enhancing endosomal pH (making the environment unfavorable) which is required for virus-cell fusion. This drug may also block viral infection by inhibiting viral enzymes or processes like viral DNA and RNA polymerases, virus assembly, new virus particle transport, immunomodulation of cytokine release and virus release. CLQ also affects the glycosylation process of ACE2 (as discussed earlier that to enter the host cell, the viral S protein binds with this receptor) [11, 14, 43, 44]. Besides this mechanism, a recent report [12] showed that this drug also acts by inhibiting the sialic acid containing glycoprotein and gangliosides (act as primary attachment factors along the respiratory tract) mediated attachment to the S protein which is the first step for viral replication. In the NTD of the S protein of SARS-CoV-2, a ganglioside-binding site was recognized. The antimalarial drug CLQ was found to be a probable blocker of the S–ganglioside interaction. Thus, this drug may be used to fight pathogenic coronaviruses especially SARS-CoV-2 which is responsible for COVID-19. A detailed mechanism of action of CLQ and HCQ against SARS-CoV-2 is illustrated in Fig. 8. A recent report showed that the EC90 value of CLQ against the SARS-CoV-2 in VeroE6 cells was 6.9 µM, which may be clinically achievable. Although specific data are not available, this drug is able to inhibit the exacerbation of pneumonia patients with SARS-CoV-2 infection.
Figure 8 explains two possible mechanisms of CLQ and HCQ against SARS-CoV-2. The mechanism 1 is that CLQ and its derivative HCQ are weak bases, which can raise the pH of acidic intracellular organelles, such as endosomes/lysosomes, essential for membrane fusion. On the other hand, mechanism-2 explains the entry of SARS-CoV-2 into the host cells also depends upon sialic acid (Neu5Ac) containing glycoproteins and gangliosides that act as the key binding factors along the respiratory tract. A ganglioside-binding site at the N-terminal domain (NTD) of the S glycoprotein of SARS-CoV-2 was recognized, and CLQ was found to be a possible blocker of the S–ganglioside interaction which occurs in the first step of the viral replication cycle (i.e., attachment to the surface of respiratory cells, intermediated by the S protein) [12]. The interaction was augmented by placing the negative charge of the carboxylate anion of Neu5Ac and one of the two positive charges of CLQ. SARS-CoV-2 especially interacted with 9-O-acetyl-N-acetylneuraminic acid (9-O-SIA). In this case, the carboxylic acid group of the sialic acid interacted with the cationic group of the nitrogen-containing ring of CLQ. The formed complex of CLQ and 9-O-SIA was further stabilized by OH-π and van der Waals interactions. Next, the complex developed from HCQ was very close to that obtained from CLQ, although numerous conformational adjustments happened for the period of the simulations. Interestingly, the –OH group of HCQ reinforced the binding of CLQ to Neu5Ac via formation of a hydrogen bond. The formed complex of CLQ-OH and 9-O-SIA will be stabilized again like CLQ to form a protective layer against fusion of the SARS–CoV-2.
HCQ is a hydroxy derivative of CLQ, which can block the viral infection by a similar mechanism as chloroquine; thus, this drug may also be a potential candidate against SARS-CoV-2. This drug is less toxic (~ 40%) than chloroquine in animals. It was found that there were seven clinical trials registered as on February 23, 2020, in the Chinese Clinical Trial Registry (http://www.chictr.org.cn), for using HCQ to treat COVID-19. The in vitro results suggested that this drug can efficiently inhibit SARS-CoV-2 infection. Based on an in vitro report, it was suggested that HCQ may be more potent than CLQ to treat COVID-19 [11, 44]. (EC50 values for CLQ > 100 µM at 24 h and 18.01 µM at 48 h; EC50 values for HCQ were 6.25 µM at 24 h and 5.85 µM at 48 h). Due to the relatively low selectivity index (SI) of HCQ, it requires cautious designing and conducting of clinical trials to attain resourceful and safe control of the SARS-CoV-2 infection.
Favipiravir or Favilavir (Avigan)
A purine nucleoside presently labeled as Avigan, developed by Fujifilm Toyama Chemical of Japan, has recently been approved for Phase-III clinical trial (March 31, 2020) for the COVID-19 patients. This drug is approved for manufacturing and sale in Japan for the treatment of influenza as an antiviral. In case of Influenza virus, it selectively inhibits RNA polymerase which is essential for viral replication when human cells are infected. It is believed that this drug may be effective for the treatment of COVID-19 as SARS-CoV-2 uses same enzyme (RNA polymerase) for replication and classification into the same type of single-stranded RNA virus like influenza. Thus, this drug acts by inhibiting the RdRp leading to inaccurate viral RNA synthesis (Fig. 6). This drug is recommended by the director of the China National Center for Biotechnology Development under the Ministry of Science and Technology to treat COVID-19. Italy has also approved the drug to treat COVID-19 cases. Due to the effectiveness of this drug against COVID-19, it is being mass-produced as generic version in China [45, 46].
Ritonavir and lopinavir (Kaletra)
These drugs are approved HIV-1 protease inhibitors, used in combination with other anti-retroviral drugs to treat HIV-1 infection in both adults and pediatric patients who is older than 14 days. Coronaviruses encode either two or three protease enzymes like papain-like proteases (PLpro), a serine-type protease, the main protease, or Mpro which cleave the polyproteins into non-structural polyproteins (nsps). These nsps are essential for viral RNA synthesis. Ritonavir and lopinavir act by inhibiting these protease enzymes. The mechanisms of action of these drugs suppressing coronavirus activity [47] are depicted in Fig. 6. A combination of these drugs is recommended in Italy to treat COVID-19 patients. Several trials are going on worldwide using these drugs or in combination of other drugs. A collaborative research from China and the UK conducted a clinical trial to examine the effectiveness of a combination of these two drugs against COVID-19 which was published in the New England Journal of Medicine (NEJM) [15]. The output of their trial did not provide any significant benefit in the patients with COVID-19. They suggest that “future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit.” Among those trials, two trials are investigating against pneumonia caused by COVID-19. One trial is conducted in the Tongji Hospital, Wuhan, China, using lopinavir–ritonavir against Arbidol hydrochloride (influenza drugs) and oseltamivir (NCT04255017). In South Korea, a comparative study of lopinavir–ritonavir against HCQ in patients with mild cases of COVID-19 (NCT04307693) was made. The two arms of the WHO SOLIDARITY trial are lopinavir–ritonavir alone and in combination with interferon-beta [48].
Ivermectin
Ivermectin is an FDA-approved broad-spectrum antiparasitic drug, which recently showed in vitro antiviral activity against SARS-CoV-2. It acts by inhibiting the interaction between HIV-1 integrase protein (IN) and the importin (IMP) α/β1 heterodimer which is responsible for IN nuclear import [49, 50]. Therefore, (IMP) α/β1 is unable to bind to the viral protein and preventing it from entering the nucleus, thus inhibiting HIV-1 replication [49, 50]. As a result, inhibition of the antiviral responses is reduced leading to a normal, more efficient antiviral response.
Monoclonal antibodies
The trial of potential monoclonal antibody-based therapy against COVID-19 is going on by using the previous knowledge on the neutralizing monoclonal antibodies (nMAb) against similar coronaviruses such as SARS-CoV and MERS-CoV. Monoclonal antibodies targeting the vulnerable sites of trimeric spike (S) glycoproteins on the viral surface which are responsible for the entry to the host cell are increasingly being recognized as a promising class of drugs against COVID-19. Potential neutralizing monoclonal antibodies mainly targeting the receptor-interaction domain at S1 subunit ultimately disabled cell–receptor interactions [51,52,53]. The detailed mechanism of action of this class of drugs is depicted in Fig. 9. Recently, several monoclonal antibodies, namely tocilizumab (atlizumab), mavrilimumab, lenzilumab, leronlimab, gimsilumab, sarilumab, siltuximab (Sylvant), camrelizumab (AiRuiKa), eculizumab (Soliris), etc., are being tried to investigate their potency against COVID-19 disease, and these are tabulated in Table 1.
The human monoclonal antibodies (hmAbs) are developed by using several strategies against SARS-CoV-2 including preparation of hybridomas (using a transgenic mouse), phage display technologies and the immortalization of convalescent B cells. At present, the hmAbs production has been carried out with two strains of transgenic mice, i.e., Medarex HuMab-Mouse and Xeno-mouse [54]. The difference between these two strains of mice is that mouse L chain genes are still functional in the Medarex HuMAb-Mouse; thus, these mice can produce chimeric mAbs. The Xeno-Mouse from Amgen has all the mouse L chain genes deleted, and B cells produce only human Abs. One of these mice monoclonal antibodies [chimeric (Medarex HuMAb) (or) hybridomas (Xeno-mouse)] was immunized to produce neutralizing antibodies and further evaluated. The developed neutralizing antibodies bind to a specific portion to the RBD (N-terminal (amino acids 12–261, 130–150), and C-terminal of the RBD (amino acids 548–567, 607–627)) to prevent fusion of SARS-CoV-2 with the target cells.
COVID-19 convalescent plasma
Due to emergency of COVID-19 patients, recently, FDA has recommended to healthcare providers and investigators the use of convalescent plasma collected from individuals who have recovered from COVID-19 that may contain antibodies to SARS-CoV-2. However, till now, this therapy has not yet been shown to be effective and safe against this disease. Thus, it is very essential to investigate the safety and effectiveness of COVID-19 convalescent plasma in clinical trials. For this therapy, FDA has recommended some guidelines as follows [55]: (1) the pathways for use of investigational COVID-19 convalescent plasma; (2) patient eligibility; (3) collection of COVID-19 convalescent plasma, including donor eligibility and donor qualifications; (4) labeling, and (5) record keeping.
The pharmacological safety data including dose, drug–drug interactions and toxicities of selected potential drug candidates are provided in Table 2.
Vaccines
Due to the worldwide outbreak of the COVID-19, the general public are keenly watching the progress of development of COVID-19 vaccines [56]. Dr. Anthony S. Fauci, Director of National Institute of Allergy and Infectious Diseases (NIAID), said that “finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority.” But development of a new vaccine against a new disease is not an easy task. Various research institutes and industries are giving their full efforts to develop a vaccine against this pandemic disease with its earliest. Thankfully, the progress is rapid due to various reasons such as: (1) sharing the efforts to sequence the genetic material of SARS-CoV-2 by China throughout the world, (2) coronaviruses were already on the radar of health science researchers, (3) the knowledge from SARS and MERS caused by corona viruses and (4) also learnings from the vaccines against SARS and MERS which were stopped or postponed when those outbreaks were controlled may still be used to defeat COVID-19. The progress of most promising vaccines against the pandemic disease COVID-19 being made by various industries and research institutes is tabulated in Table 3. Several miscellaneous vaccines under investigation for COVID-19 are listed under Box 2.
In silico modeling applied to search the future drug candidates
To combat the COVID-19 pandemic, researchers must fight with the time to save as many lives as possible. To save the time and speed up the drug discovery process, in silico modeling provides one the best possible options. Till now, in most of the cases, researchers are trying the computational repurposing theory of existing approved drugs (synthetic as well as from natural origin) for SARS-CoV-2 employing docking, homology modeling and molecular dynamics (MD) studies to identify probable magic drugs for COVID-19. Huang et al. [21] computationally designed a short protein fragment or peptide which may block the coronaviruses’ ability to enter human cells by binding to the viral protein which is one of the first kinds of peptide treatments routing for experimental efforts.
Smith and Smith [22] analyzed 8000 small drug molecules and natural products (SWEETLEAD library database) employing restrained temperature replica-exchange MD simulations combining virtual screening through the ensemble docking to identify the effective drug for COVID-19 which might stop the virus by two ways: (a) disrupting S protein and ACE2 receptor interface stability; or (b) by troubling the capability of the S protein to recognize the ACE2 receptor. The simulation was performed in the IBM’s supercomputer SUMMIT which is recognized as the world’s most powerful computer with 200 petaflops speed. The authors reported the predicted binding affinities of all studied molecules for isolated SARS-CoV-2 S protein and the S protein human ACE2 receptor interface, followed by proposed 77 small molecules by docking studies (47 ligands employing interface docking and 30 ligands identified by the isolated S protein docking). Among the identified 77 molecules, the authors finally reported top 7 regulatory approved small molecules [Pemirolast (Zinc ID: 5783214), Isoniazid pyruvate (Zinc ID: 4974291), Eriodictyol (Zinc ID: 58117) and Nitrofurantoin (Zinc ID: 3875368) binding within the S protein-ACE2 interface; Ergoloid (Zinc ID: 3995616), Cepharanthine (Zinc ID: 30726863), and Hypericin (Zinc ID: 3780340) binding with the S protein receptor] which may serve as possible drug candidates for COVID-19 (Fig. 10a).
Ton et al. [23] identified 1000 noncovalent inhibitors for SARS-CoV-2 main protease (Mpro) using 1.36 billion compounds from the ZINC15 library employing deep docking platform using Glide SP module which utilizes QSAR models trained on docking scores. The 4MDS protein with 1.6 Å resolution bound to a noncovalent inhibitor was used for the docking study, and among the identified 1000 noncovalent inhibitors, ZINC000541677852 is the top hit drug candidate (Fig. 10b).
α-Ketoamide inhibitors are proposed as new drug candidates by designing, synthesis, followed by a docking study on the main protease (Mpro, 3CLpro) which has a crucial role in processing the polyproteins that are translated from the viral RNA [24]. Three different PDB structures were employed for the study; they are 6Y2E, 6Y2F and 6Y2G. The authors modified previously designed inhibitor (1) (earlier used for beta-, alpha coronaviruses and 3C proteases of enteroviruses) by incorporating the P3-P2 amide bond into a pyridone ring to enhance the half-life of the newly designed (2) compound in plasma followed by replacing the hydrophobic cinnamoyl moiety with less hydrophobic Boc group (Fig. 11a). Although the inhibitory concentration decreased from 0.18 ± 0.02 µM (1) to 2.39 ± 0.63 µM (2), but molecule 2 reported three times higher plasma binding and 19 times better plasma solubility compared to molecule 1. Further, to improve the antiviral activity against betacoronaviruses of clade b, the authors replaced the P2 cyclohexyl moiety of molecule 1 by the smaller cyclopropyl fragment to produce compound 3 which showed IC50 value of 0.67 ± 0.18 μM for the purified recombinant SARS-CoV-2 Mpro.
Zhou et al. [25] reported an integrative antiviral drug repurposing analysis employing pharmacology-based network medicine platform by a two-step process: (a) quantifying the relationship between the human coronaviruses (HCoV) and host interactome and (b) identifying the drug targets in the human protein–protein interaction network. As per phylogenetic analyses, SARS-CoV-2 has the highest nucleotide sequence identity (79.7%), followed by the envelope and nucleocapsid protein sequence identities of 96% and 89.6%, respectively, with SARS-CoV. Employing the network proximity analyses between drug targets and HCoV-associated proteins followed by gene set enrichment analysis (GSEA), it was possible to identify 16 probable anti-HCoV drugs (e.g., melatonin, mercaptopurine, and sirolimus, etc.). Later, the drugs were validated through HCoV-induced transcriptomics data in human cell lines and enrichment analyses of drug-gene signatures. The authors also reported three effective drug combinations among the probable hits identified through ‘complimentary exposure’ pattern (Fig. 11b).
Grifoni et al. [26] employed the Immune Epitope Database and Analysis Resource (IEDB) to characterize the sequence similarity between SARS-CoV and SARS-CoV-2 through homology modeling. The epitope prediction identified a priori potential B and T cell epitopes for SARS-CoV-2 which are the promising targets for immune recognition, followed by the discovery of diagnostics and future vaccines.
Within a short period of time, a huge number of in silico results were deposited in the preprint servers from all over the world and at the same time a few are already published. As in most of the cases, multiple in silico drug designing and virtual screening tools were employed for repurposing theory of approved existing drugs [94], thus, major information is gathered in Table 4 to avoid similar discussion several times [95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119].
An interesting aspect is that most of the studies are based on repurposing theory of existing approved drug employing docking and MD supported VS. Majorly the authors relied on approved antiviral drugs along with DrugBank database, Zinc database, Natural compounds’ databases along with one of the most discussed molecules of recent time, HCQ. Thus, the basic ideas of implication of in silico tools and repurposing of approved drugs are same, but the only difference is selection of the target protein in different studies. Without any doubt, the crystal structure of COVID-19 main protease (Mpro) in complex with an inhibitor N3 (PDB: 6LU7) is the most accessed protein for the drug discovery. But based on the target type, the choice of proteins can be different. Thus, to assist researchers, we have classified the target proteins into 14 types covering 110 PDB crystal ID from PDB (https://www.rcsb.org/) available until April 12, 2020, and enlisted in Table 5.
Is interspecies modeling the future of COVID-19 drug discovery? An unexplored concept under in silico tools
Multiple incidents illustrated the outbreak of corona virus in animals, especially in pets [120, 121]. Animals from dogs, cats, tigers, lions to minks are already tested positive and showed mild to severe symptoms of corona virus, followed by death of few instances. Although these events are scattered and not enough to study in the middle of human crisis, we cannot ignore the fact of human to animal transmission. If human to animal transmission is true, then there is a possibility of mutations, insertions and deletions in the genome sequence of this deadly virus in these animals in future with probabilities of zoonotic transfer of a stronger form of present SARS-CoV-2 virus from them to human in the near future. Thus, these small incidents need to be checked very carefully to avoid any future transmission.
The above-mentioned facts help to build an interspecies analysis by Kar and Leszczynski [122] for animals to human transmission or vice versa to aid in the drug discovery process of COVID-19 in upcoming days. The in silico interspecies-quantitative structure–activity relationship (i-QSAR) modeling correlates and then extrapolates the response (activity/toxicity) data from animal source to human which will be helpful for drug discovery. Due to genome sequence similarity of SARS-CoV-2 with the pangolins and bat, experimental data of drug candidates to pangolins/bat along with structural and physicochemical properties of drugs can be correlated with human response endpoint which is the first step of modeling. In the next step, extrapolation of animal data to human data can lead to no human testing through developed i-QSAR model. Once the acceptable predictive i-QSAR model is ready, there might be no need of future animal testing. As bat and pangolins are endangered species, thus future introspection can be performed in dogs and cats due to their better accessibility as well as considering them possible carriers of SARS-CoV-2 from the recent incidents.
Conclusion
Researchers from all over the world are trying to find the medicines which will help to stop the transmission of the virulent SARS-CoV-2 virus, mitigate the symptoms of the infected patients and help to lower the death toll throughout the world. Unfortunately, till now there is no silver gunshot which can solve this pandemic COVID-19. We have reported here a comprehensive and updated discussion on drug or drug candidates under investigation with their probable targets and mechanisms of action which might not be clear for many cases earlier, along with the effort of ongoing vaccine trials, monoclonal antibodies therapy and convalescent plasma treatment. We have presented here the ongoing computational efforts related to in silico tools to explore the probable drug candidates against COVID-19 along with the up-to-date target protein information. The information provided from in silico approaches may work as a magic bullet for the medicinal chemists to accelerate the drug discovery and development process. Overall, this review provides a strong intellectual foundation to support progress of ongoing research related to thorough knowledge of drugs or investigational drugs, vaccines and in silico approaches which can be helpful for the development of new drug candidates for the treatment of COVID-19.
References
Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579:265–269
Zhou P, Yang X-L, Wang X-G et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273
COVID-19 Coronavirus pandemic data. https://www.worldometers.info/coronavirus/. Accessed 11 May 2020
Zeng ZQ, Chen DH, Tan WP et al (2018) Epidemiology and clinical characteristics of human coronaviruses OC43, 229E, NL63, and HKU1: a study of hospitalized children with acute respiratory tract infection in Guangzhou, China. Eur J Clin Microbiol Infect Dis 37:363–369
Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733
Li X, Zai J, Wang X, Li Y (2020) Potential of large “first generation” human-to-human transmission of 2019-nCoV. J Med Virol 92:448–454
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E (2020) The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir Res 176:104742
Song W, Gui M, Wang X, Xiang Y (2018) Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 14:e1007236
Liu C, Zhou Q, Liet Y et al (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6:315–331
Fung TS, Liu DX (2019) Human coronavirus: host–pathogen interaction. Annu Rev Microbiol 73:529–557
Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237
Fantini J, Di Scala C, Chahinian H, Yahi N (2020) Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J AntiMicrob Agents 55:105960. https://doi.org/10.1016/j.ijantimicag.2020.105960
Gautret P, Lagierac J-C, Parola P et al (2020) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis 34:101663
Wang M, Cao R, Zhanget L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271
Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787–1799
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04470427. Accessed 13 Aug 2020
Phase I Clinical Trial of a COVID-19 Vaccine in 18–60 Healthy Adults (CTCOVID-19). ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04313127. Accessed 11 May 2020
A Study of a Candidate COVID-19 Vaccine (COV001). ClinicalTrials.gov website: https://www.clinicaltrials.gov/ct2/show/NCT04324606. Accessed 11 May 2020
de Vrieze J (2020) Can a century-old TB vaccine steel the immune system against the new coronavirus? Science. https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus. Accessed 11 May 2020
BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE). ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04327206. Accessed 11 May 2020
Huang X, Pearce R, Zhang Y (2020) Computational design of peptides to block binding of the SARS-CoV-2 spike protein to human ACE2. Preprint at https://www.biorxiv.org/content/10.1101/2020.03.28.013607v1.full.pdf
Smith M, Smith JC (2020) Repurposing therapeutics for covid-19: Supercomputer-based docking to the sars-cov-2 viral spike protein and viral spike protein-human ace2 interface. Preprint at https://doi.org/10.26434/chemrxiv.11871402.v3
Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A (2020) Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol Inform 39:2000028. https://doi.org/10.1002/minf.202000028
Zhang L, Lin D, Sun X et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 368:409–412
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell discov 6:1–18
Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A (2020) A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27:671–680
Wang LS, Wang YR, Ye DW, Liu QQ (2020) A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents 55:105948. https://doi.org/10.1016/j.ijantimicag.2020.105948
Wu D, Wu T, Liu Q, Yang Z (2020) The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 94:44–48
Yang P, Wang X (2020) COVID-19: a new challenge for human beings. Cell Mol Immunol 17:555–557
Bouadma L, Lescure FX, Lucet JC, Yazdanpanah Y, Timsit JF (2020) Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. Intensive Care Med 46:579–582
Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S (2009) The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol 7:226–236
Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S (2017) MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 21:131–143
Novel coronavirus structure reveals targets for vaccines and treatments (2020) https://www.nih.gov/news-events/nih-research-matters/novel-coronavirus-structure-reveals-targets-vaccines-treatments. Accessed 11 May 2020
Gurwitz D (2020) Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 81:537–540. https://doi.org/10.1002/ddr.21656
Glowacka I, Bertram S, Herzog P et al (2010) Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol 84:1198–1205
Wu Y (2020) Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. Virol Sin 35: 256–258. https://doi.org/10.1007/s12250-020-00205-6
Li G, De Clercq E (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:149–150
The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI). ClinicalTrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04252885. Accessed 11 May 2020
Kadam RU, Wilson IA (2017) Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci 114:206–214
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271–280
Martinez MA (2020) Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 64:e00399-20
Holshue ML, DeBolt C, Lindquist S et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936
Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72–73
Al-Bari MAA (2017) Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharmacol Res Perspect 5:e00293
Maxmen A (2020) More than 80 clinical trials launch to test coronavirus treatments. Nature 578:347–348
Mifsud EJ, Hayden FG, Hurt AC (2019) Antivirals targeting the polymerase complex of influenza viruses. Antivir Res 169:104545
Liu X, Wang XJ (2020) Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics 47:119–121
Lopinavir; Ritonavir (All Populations Monograph). Elsevier (2020) https://www.elsevier.com/__data/assets/pdf_file/0010/990730/Lopinavir,-Ritonavir-Drug-Monograph_3.17.2020.pdf. Accessed 11 May 2020
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res 178:104787
Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA (2011) An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import. J Biomol Screen 16:192–200
Yu X, Zhang S, Jiang L et al (2015) Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci Rep 5:13133
Widjaja I, Wang C, van Haperen R et al (2019) Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect 8:516–530
Tian X, Li C, Huang A et al (2020) Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 9:382–385
Scott CT (2007) Mice with a human touch. Nat Biotechnol 25:1075–1077
Recommendations for Investigational COVID-19 Convalescent Plasma, US FDA (2020) https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds?utm_campaign=What%27sNew2020-03-24&utm_medium=email&utm_source=Eloqua. Accessed 11 May 2020
Ahmed SF, Quadeer AA, McKay MR (2020) Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12:254
Sheahan TP, Sims AC, Leist SR et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222
Guo D (2020) Old weapon for new enemy: drug repurposing for treatment of newly emerging viral diseases. Virol Sin 35:253–255. https://doi.org/10.1007/s12250-020-00204-7
Expanded Access Remdesivir (RDV; GS-5734™). ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/results?cond=Coronavirus&term=&type=&rslt=&age_v=&gndr=&intr=remdesivir&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=. Accessed 11 May 2020
‘Favilavir’: First approved drug to possibly treat coronavirus. The Science Times. https://www.sciencetimes.com/articles/25053/20200317/favilavir-first-approve-drug-treat-coronavirus.htm. Accessed 11 May 2020
Favipiravir combined with tocilizumab in the treatment of Corona Virus Disease 2019. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04310228?cond=Coronavirus&intr=Tocilizumab&draw=2&rank=1. Accessed 11 May 2020
Arabi YM, Shalhoub S, Mandourah Y et al (2020) Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis 70:1837–1844
Liu W, Morse JS, Lalonde T, Xu S (2020) Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 21:730–738
Surviving sepsis campaign rapid guidelines of the management of critically ill adults with coronavirus disease 2019. ESICM. https://www.esicm.org/ssc-covid19-guidelines/. Accessed 11 May 2020]
Harrison C (2020) Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 38:379–391
Velavan TP, Meyer CG (2020) The COVID-19 epidemic. Trop Med Int Health 25:278–280
De Witt BJ, Garrison EA, Champion HC, Kadowitz PJ (2020) L-163,491 is a partial angiotensin AT1 receptor agonist in the hindquarters vascular bed of the cat. Eur J Pharmacol 404:213–219
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30–e31
Xu X, Han M, Li T et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab. PNAS 117:10970–10975. https://doi.org/10.1073/pnas.2005615117
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia. Roche. https://www.roche.com/media/releases/med-cor-2020-03-19.htm. Accessed 11 May 2020
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation. PipelineReview. https://pipelinereview.com/index.php/2020040174191/Antibodies/Kiniksa-Announces-Early-Evidence-of-Treatment-Response-with-Mavrilimumab-in-6-Patients-with-Severe-COVID-19-Pneumonia-and-Hyperinflammation.html. Accessed 11 May 2020
Craven J COVID-19 therapeutics tracker. Regulatory Focus. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker. Accessed 11 May 2020
Fitzhugh M Humanigen preps lenzilumab for potential battle with deadly COVID-19 symptom. Bioworld. https://www.bioworld.com/articles/433890-humanigen-preps-lenzilumab-for-potential-battle-with-deadly-covid-19-symptom. Accessed 11 May 2020
FDA Approves Emergency IND Use of Humanigen’s Lenzilumab For Compassionate Use In COVID-19 Patients. ACCESSWIRE. https://www.accesswire.com/583610/FDA-Approves-Emergency-IND-Use-of-Humanigens-Lenzilumab-For-Compassionate-Use-In-COVID-19-Patients. Accessed 11 May 2020
Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab. CytoDyn. https://content.equisolve.net/_7bdf444ef2b4daaec17d4324fda3a32a/cytodyn/news/2020-04-07_Novant_Health_Initiates_Phase_2_COVID_19_Trial_411.pdf. Accessed 11 May 2020
Roivant pushing gimsilumab testing for ARDS in COVID-19 patients. ThePharmaLetter. https://www.thepharmaletter.com/article/roivant-pushing-gimsilumab-testing-for-ards-in-covid-19-patients. Accessed 11 May 2020
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19. https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/media-room/press-releases/2020/2020-03-30-07-00-00-2008040-en.pdf. Accessed 11 May 2020
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress. P&T Community. https://www.ptcommunity.com/wire/relief-therapeutics-and-neurorx-inc-file-fda-ind-aviptadil-treat-covid-19-induced-respiratory. Accessed 11 May 2020
EUSA Launches Trial of Siltuximab for COVID-19 Complications. FDA NEWS. https://www.fdanews.com/articles/196378-eusa-launches-trial-of-siltuximab-for-covid-19-complications. Accessed 11 May 2020
Immunoregulatory Therapy for 2019-nCoV. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04268537. Accessed 11 May 2020
Alexion to start Soliris in COVID-19 Phase II trial in next few days. GlobalData. https://www.globaldata.com/alexion-to-start-soliris-in-covid-19-phase-ii-trial-in-next-few-days-says-globaldata/. Accessed 11 May 2020
Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04275414. Accessed 11 May 2020
CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID). ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04317040. Accessed 11 May 2020
Colchicine Counteracting Inflammation in COVID-19 Pneumonia (ColCOVID-19). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04322565. Accessed 11 May 2020
Covid-19 drug research: second phase of clinical trial of new drug candidate, SNG001 For SARS-CoV-2 coronavirus initiated. Thailand Medical News. https://www.thailandmedical.news/news/covid-19-drug-research-second-phase-of-clinical-trial-of-new-drug-candidate,-sng001-for-sars-cov-2-coronavirus-initiated. Accessed 11 May 2020
BIDMC launches clinical trial to assess common anti-clotting medication for treatment of COVID-19-related respiratory failure. BIDMC. https://www.bidmc.org/about-bidmc/news/2020/04/covid-19-anti-clotting-medication. Accessed 11 May 2020
Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 11 May 2020
Use of Ascorbic Acid in Patients with COVID 19. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04323514. Accessed 11 May 2020
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB (2020) Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323:1824–1836. https://doi.org/10.1001/jama.2020.6019
Immunity and safety of Covid-19 synthetic minigene vaccine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04276896. Accessed 11 May 2020
Evaluating the safety, tolerability and immunogenicity of bacTRL-spike vaccine for prevention of COVID-19. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04334980. Accessed 11 May 2020
COVID-19 Treatment and Vaccine Tracker. Milken Institute (2020). https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf?fbclid=IwAR2rX6EhbvBMcGf3eqnQNimiz1u7KPJVM3aeXN1HmgmCX3QlfbVTrcV3cQQ. Accessed 11 May 2020
Craven, J. COVID-19 vaccine tracker. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker. Accessed 15 August 2020
Roy K (2019) In silico drug design: repurposing techniques and methodologies. Academic Press, New York
Han Y, Kral P (2020) Computational design of ACE2-based short peptide inhibitors of SARS-CoV2. ChemRxiv. Preprint at https://doi.org/10.26434/chemrxiv.12061734.v1
Talluri S (2020) Virtual screening based prediction of potential drugs for COVID-19. Preprints at https://doi.org/10.20944/preprints202002.0418.v2
Contini A (2020) Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins. Preprint at https://doi.org/10.26434/chemrxiv.11847381
Hosseini FS, Amanlou M (2020) Simeprevir, potential candidate to repurpose for coronavirus infection: virtual screening and molecular docking study. Preprints at https://doi.org/10.20944/preprints202002.0438.v1
Wang J (2020) Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. Preprint at https://doi.org/10.26434/chemrxiv.11875446.v1
Shaghaghi N (2020) Molecular docking study of novel COVID-19 protease with low risk terpenoides compounds of plants. Preprint at https://doi.org/10.26434/chemrxiv.11935722.v1
Chakraborti S, Bheemireddy Sneha, Srinivasan, N (2020) Repurposing drugs against main protease of SARS-CoV-2: mechanism based insights supported by available laboratory and clinical data. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.12057846.v2
Mendoza-Martinez C, Rodriguez-Lezama A (2020) Identification of potential inhibitors of SARS-CoV2 main protease via a rapid in-silico drug repurposing approach. Preprint at https://doi.org/10.26434/chemrxiv.12085083.v1
Zhang DH, Wu KL, Zhang X, Deng SQ, Peng B (2020) In silico screening of Chinese herbalmedicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med 18:152–158
Wu C, Liu Y, Yang Y et al (2020) Analysis of therapeutic targets for SARS-CoV2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 10:766–788. https://doi.org/10.1016/j.apsb.2020.02.008
Beck BR, Shin B, Choi Y, Park S, Kang K (2020) Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV2) through a drug-target interaction deep learning model. Comput Struct Biotechnol 18:784–790
Sharma A, Tiwari V, Sowdhamini R (2020) Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products. Preprint at https://doi.org/10.26434/chemrxiv.12091356.v1
Choudhary S, Malik YS, Tomar S (2020) Identification of SARS-CoV2 cell entry inhibitors by drug repurposing using in silico structure-based virtual screening approach. Preprint at https://doi.org/10.26434/chemrxiv.12005988.v1
Chen YW, Yiu CPB, Wong KY (2020) Prediction of the SARS-CoV2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research 9:129
Oliveira LD, Davi M, Oliveira TD, Mota K (2020) Comparative computational study of SARS-CoV2 receptors antagonists from already approved drugs. Preprint at https://doi.org/10.26434/chemrxiv.12044538.v2
Thuy BTP, My TTA, Hai NTT et al (2020) Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil. ACS Omega 5:8312–8320
Sehailia M, Chemat S (2020) In-silico studies of antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19. Preprint at https://doi.org/10.26434/chemrxiv.12098652.v1
Fantini J, Scala CD, Chahinian H, Yahi N (2020) Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV2 infection. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105960
Srivastava A, Singh D (2020) Destabilizing the structural integrity of SARS-CoV2 receptor proteins by curcumin along with hydroxychloroquine: an insilco approach for a combination therapy. Preprint at https://doi.org/10.26434/chemrxiv.12090438.v1
Mittal L, Kumari A, Srivastava M, Singh M, Asthana S (2020) Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. Preprint at https://doi.org/10.26434/chemrxiv.12086565.v2
Kumar V, Roy K (2020) Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3Clike protease (3CLpro) enzyme inhibitors against SARS-CoV diseases. SAR QSAR Environ Res 31:511–526. https://doi.org/10.1080/1062936X.2020.1776388
Andrade BS, Ghosh P, Barh D, Tiwari S, Silva RJS, Soares WRDA, Melo TS, Freitas AS, González-Grande P, Palmeira LS, Alcantara LCJ, Giovanetti M, Góes-Neto A, Azevedo VADC (2020) Computational screening for potential drug candidates against the SARS-CoV-2 main protease [version 1; awaiting peer review]. F1000Research 9:514. https://doi.org/10.12688/f1000research.23829.1
Onawole AT, Sulaiman KO, Kolapo TU, Akinde FO, Adegoke RO (2020) COVID-19: CADD to the rescue. Virus Res 285:198022
Santibáñez-Morán MG, López-López Edgar, Prieto-Martínez FD, Sánchez-Cruz Norberto, Medina-Franco JL (2020) Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease. Preprint at https://doi.org/10.26434/chemrxiv.12420860.v1
Kapusta K, Kar S, Collins JT, Franklin LM, Kolodziejczyk W, Leszczynski J, Hill GA (2020) Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (Mpro) through docking, molecular mechanic & dynamic, and ADMET Profiling. Struct Dyn, J Biomol. https://doi.org/10.1080/07391102.2020.1806930
Grimm D (2020) Should pets be tested for coronavirus? Science. https://doi.org/10.1126/science.abc0029
Shi J, Wen Z, Zhong G et al (2020) Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS coronavirus-2. Science 368:1016
Kar S, Leszczynski J (2020) From animal to human–interspecies analysis provides novel way of ascertaining and fighting COVID-19. The Innovation. https://doi.org/10.1016/j.xinn.2020.100021
Acknowledgements
PKO thanks the UGC, New Delhi, for financial assistance in the form of a fellowship (F./PDFSS-2015-17-WES-11996). SK and JL are thankful to the National Science Foundation (NSF/CREST HRD-1547754 and NSF/RISE HRD-1547836) for financial support. JGK thanks the Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, Government of India, and the National Institute of Pharmaceutical Education and Research Kolkata (NIPER-Kolkata) for providing financial assistance in the form of a fellowship. KR thanks Science and Engineering Research Board (SERB), New Delhi, for financial assistance under the MATRICS scheme (File Number MTR/2019/000008).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
There are no conflicts to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ojha, P.K., Kar, S., Krishna, J.G. et al. Therapeutics for COVID-19: from computation to practices—where we are, where we are heading to. Mol Divers 25, 625–659 (2021). https://doi.org/10.1007/s11030-020-10134-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-020-10134-x